Crinos Industria Farmacobiologica S.p.a.

Gentium S.p.a.

Gentium S.r.l.

Instituto Luso Farmaco D'italia S.p.a.

Gentum S.p.a.

Roberto Porta

Laura Ferro

Giuseppe Prino

Marisa Mantovani

Ennio Lanzarotti

Armando Cedro

Danilo Moltrasio

Fabio Trento

Massimo Iacobelli

Rodolfo Pescador

Franco Cattaneo

Carmelo Carlo Stella

Giangiacomo Torri

Benito Casu

Elso Manghisi

Annamaria Naggi

Giuseppe Cascio

Giancarlo B Fregnan

Alessandro Massimo Gianni

Cedro Armando

Massimo Alessandro Gianni

Enea Menegatti

Pia Alberico

Manlio Palumbo

Barbara Gatto

Elisabetta Esposito

Claudio Nastruzzi

The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Formulation having mobilizing activity

Formulation having mobilising activity

The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.

DNA-based aptamers for human cathepsin G

Method for determining the biological activity of defibrotide by a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.

Method for determining the biological activity of defibrotide

The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.

Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments

Agents and compositions thereof for the hair treatment

Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity. Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Fucans with low molecular weight having anticoagulant, antithrombinic

The invention discloses new oligodeoxyribonucleotides of animal origin, having a molecular weight comprised between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new compounds are endowed with a significant anti-ischemic activity.

Process producing lower molecular weight range oligodeoxyribonucleotides

There are provided oligodeoxyribonucleotides of animal origin, having a molecular weight between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The compounds are endowed with a significant anti-ischemic activity.

Treatment of cardiac ischemia by administration of a fraction of

Pharmaecutical composition for topical use containing Defibrotide have been found effective in the therapy of local pathologies characterized by a reduced resistance of the blood capillary vessels.

Pharmaceutical composition for topical use in the treatment of the

Novel derivatives are disclosed as obtained from chondroitin sulfate, dermatan sulfate and hyaluronic acid, having a molar ratio between sulfate groups and carboxylic groups like that of heparin and furthermore characterized by possessing, as the heparin, the sulfoamino group at the carbon atom at the 6 position of hexosamine. The novel compounds show a very remarkable clearing activity in comparison with the starting mucopolysaccharides, this activity being similar and for some derivatives comparable with that of heparin. Moreover, differently from what normally happens upon sulfating the sulfomucopolysaccharides, the anticoagulating activity of the novel compounds is negligible or anyhow very reduced. The compounds of the present invention find use in the therapy of arteriosclerosis.

Sulfoamino derivatives of chondroitin sulfates of dermatan sulfate and

The invention provides novel 4-aryl-5-aminoalkyl-1,3-dioxol-2-ones having hypocholesterolemic, hypolipemic, antiulcer, antihistaminic and antiserotoninic activities.

4-Aryl-5-piperazinoalkyl-1,3-dioxol-2-ones, and compositions

Growing community of inventors

Cernobbio, Italy

Roberto Porta